文献速递甲状腺与浅表介入US

预测超声引导热消融治疗原发性甲状旁腺功能亢进的获益

Predicting ultrasound-guided thermal ablation benefit in primary hyperparathyroidism.
PubMed 文献 · Eur Radiol · 2022-06-16

本研究纳入148例原发性甲状旁腺功能亢进患者,分为开发队列104例和外部验证队列44例,评估基于甲状旁腺激素的分类器与热消融治愈率的关系。以甲状旁腺激素269.1 pg/mL为阈值分组,低值组治愈率更高(p < 0.001),基于甲状旁腺激素的列线图在验证队列预测治愈率AUC为0.816(95%CI 0.677至0.956)。

要点

  • 甲状旁腺激素<269.1 pg/mL者热消融后治愈率高于≥269.1 pg/mL者(p < 0.001)。
  • 基于甲状旁腺激素的列线图预测治愈率,外部验证AUC为0.816(95%CI 0.677至0.956)。
  • 甲状旁腺激素是各队列中治愈率的最强预测因子,且优于临床模型。

核心结论

  • 基于甲状旁腺激素的分类器可能有助于个体化治疗规划,筛选可能从热消融中获益的患者。

研究设计与样本

  • 研究筛查171例,纳入148例(86.5%),分为开发队列104例和外部验证队列44例,评估基于甲状旁腺激素的分类器与治愈率的关系,并用逻辑回归模型构建列线图。

诊断标准与关键数值

  • 以甲状旁腺激素<269.1 pg/mL或≥269.1 pg/mL为最佳预后阈值,将患者分为低风险和高风险组。

临床应用与阅片要点

  • 作者认为基于甲状旁腺激素的分类器可能有助于个体化治疗规划,筛选可能从热消融中获益的患者。

局限性

  • 热消融后复发率在10%至15%之间。
  • 能从热消融治疗中获益的患者特征尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Ultrasound (US)-guided thermal ablation for primary hyperparathyroidism (PHPT) is a relatively novel minimally invasive treatment. The recurrence rate after ablation is between 10 and 15%. The characteristics of patients who can benefit from thermal ablation therapy are not clear yet. The aim of this research was to investigate the validity of a parathyroid hormone (PTH)-based classifier for stratifying patients with PHPT.

METHODS: A total of 171 patients were screened, 148 (86.5%) of whom were eligible and were divided into development (n = 104) and external validation (n = 44) cohorts. The potential relationship between the PTH-based classifier and the cure rate of patients was initially assessed in the primary cohort and then validated in the external validation cohort. The nomogram was computed from the logistic regression model.

RESULTS: A cut-off of PTH < 269.1 pg/mL or ≥ 269.1 pg/mL as the optimal prognostic threshold in the training cohort was generated to stratify the patients into low-risk and high-risk groups. Patients with PTH levels < 269.1 pg/mL in the training cohort had a higher cure rate than patients with PTH levels ≥ 269.1 pg/mL (p < 0.001). The PTH level remained the strongest predictor of the cure rate in all cohorts. Furthermore, a nomogram based on the PTH level was developed to predict the cure rate in the training cohort and it performed well in the external validation cohort (AUC: 0.816, 95%CI 0.703 to 0.930; AUC: 0.816, 95%CI 0.677 to 0.956).

CONCLUSIONS: The PTH-based classifier may help with individualised treatment planning for selecting patients who may benefit from thermal ablation.

KEY POINTS: • This is the first analysis of predictors affecting the outcome of US-guided thermal ablation of primary hyperparathyroidism and the findings can be used to identify the potential beneficiary population of thermal ablation of primary hyperparathyroidism. • Parathyroid hormone (PTH) was confirmed as an independent prognostic factor, as it not only showed good accuracy in stratifying patients into high- and low-risk groups in the training and validation cohorts but also outperformed the clinical model. • This study developed and validated a model to predict the treatment success of thermal ablation of primary hyperparathyroidism.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Liu, Peng, Chai, et al. Predicting ultrasound-guided thermal ablation benefit in primary hyperparathyroidism. Eur Radiol. 2022. PMID: 35708841. doi:10.1007/s00330-022-08898-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。